The Optic Neuritis Market was substantial in size in 2020 and is projected to experience a rapid increase in revenue CAGR from 2021 to 2028. Key drivers for this growth include the presence of well-established healthcare infrastructure and favorable reimbursement policies worldwide.
Optic neuritis, also known as optic papillitis and retro tubular neuritis, refers to the inflammation of the optic nerve. It is commonly associated with multiple sclerosis and can lead to partial or complete vision loss. During its early stages, optic neuritis may be diagnosed alongside other diseases such as hyperkalemia and Diabetes mellitus. The major symptoms of optic neuritis encompass partial or complete vision loss, blurred vision, eye pain, and others.
In most instances, the primary symptoms of optic neuritis consist of sensitivity to light (photophobia), redness in the eyes, and decreased night vision. Optic neuritis can be classified into two types based on the age group of patients: adult optic neuritis and pediatric optic neuritis. The inflammation of the optic nerve disrupts its proper functioning and can lead to vision loss due to the destruction of the myelin sheath connected to the optic nerve.
Approximately 40% to 50% of patients with Multiple Sclerosis (MS) experience optic neuritis, and around 30% of those with optic neuritis display signs of multiple sclerosis. A research study conducted by NCBI in 2021 revealed that the risk of optic neuritis is higher in individuals aged between 20 to 40 years.
Get a sample of the report @ https://www.reportsanddata.com/download-free-sample/4486
Major Companies Profiled in The Report:
- Pfizer
- Sanofi
- Allergan
- Bristol-Myers Squibb
- Novartis
- Healthy Life Pharma
- Fresenius Kabi USA
- Hikma
- AdvaCare Pharma
- Biogen
- Mallinckrodt Pharmaceutical
- Teijin Pharmaceutical
- Henry Schein
- Watson Pharmaceuticals
- West-Ward Pharmaceutical
To know more about the report @ https://www.reportsanddata.com/report-detail/optic-neuritis-market
The driving factors and restraints of the Optic Neuritis Market are as follows:
Driving Factors:
- Growing Prevalence of Multiple Sclerosis (MS): Optic neuritis is often associated with multiple sclerosis, a chronic autoimmune disease affecting the central nervous system. The increasing prevalence of MS worldwide is driving the demand for optic neuritis treatments and diagnosis.
- Advancements in Healthcare Infrastructure: Improvements in healthcare facilities and access to medical services are contributing to the early detection and treatment of optic neuritis, leading to an expanded market.
- Rising Awareness and Diagnosis Rates: Increasing awareness among the population and healthcare professionals about optic neuritis symptoms and risk factors is boosting the number of diagnosed cases, positively impacting market growth.
- Technological Innovations: Advancements in medical imaging technologies, such as Optical Coherence Tomography (OCT) and Magnetic Resonance Imaging (MRI), have improved the diagnosis and monitoring of optic neuritis, propelling market expansion.
- Supportive Reimbursement Policies: Favorable reimbursement policies provided by healthcare authorities and insurance companies for optic neuritis treatments are encouraging patients to seek medical help, contributing to market growth.
Restraints:
- High Treatment Costs: The cost of treating optic neuritis, especially for chronic cases, can be significant. This may limit access to proper healthcare for some patients, hindering market growth.
- Limited Awareness in Developing Regions: In certain developing regions, awareness about optic neuritis, its symptoms, and available treatments may be low, leading to delayed diagnosis and treatment, acting as a restraint on market growth.
- Adverse Effects of Medications: Some treatments for optic neuritis may have adverse side effects, making patients hesitant to undergo certain therapies, affecting market demand.
- Patent Expiry and Generic Competition: As patents for certain optic neuritis drugs expire, generic alternatives may enter the market at lower prices, impacting the revenues of branded medications.
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/4486
About Us:
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek